JP7547356B2 - Ｓｒｃキナーゼ阻害剤を使用して線維性疾患若しくは線維性状態又は間質性肺疾患を処置する方法 - Google Patents

Ｓｒｃキナーゼ阻害剤を使用して線維性疾患若しくは線維性状態又は間質性肺疾患を処置する方法 Download PDF

Info

Publication number
JP7547356B2
JP7547356B2 JP2021550035A JP2021550035A JP7547356B2 JP 7547356 B2 JP7547356 B2 JP 7547356B2 JP 2021550035 A JP2021550035 A JP 2021550035A JP 2021550035 A JP2021550035 A JP 2021550035A JP 7547356 B2 JP7547356 B2 JP 7547356B2
Authority
JP
Japan
Prior art keywords
ipf
fibrosis
pharma
fibrotic
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021550035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521635A (ja
JP2022521635A5 (https=
Inventor
カズンズ，レスリー
ニベンズ，チャド
ジェーン エスコット，キャサリン
モンクリー，スーザン
プラッセ，アンティエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2022521635A publication Critical patent/JP2022521635A/ja
Publication of JP2022521635A5 publication Critical patent/JP2022521635A5/ja
Priority to JP2024146122A priority Critical patent/JP2024174909A/ja
Application granted granted Critical
Publication of JP7547356B2 publication Critical patent/JP7547356B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021550035A 2019-02-27 2020-02-26 Ｓｒｃキナーゼ阻害剤を使用して線維性疾患若しくは線維性状態又は間質性肺疾患を処置する方法 Active JP7547356B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024146122A JP2024174909A (ja) 2019-02-27 2024-08-28 Ｓｒｃキナーゼ阻害剤を使用して線維性疾患若しくは線維性状態又は間質性肺疾患を処置する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811009P 2019-02-27 2019-02-27
US62/811,009 2019-02-27
PCT/IB2020/051642 WO2020174420A1 (en) 2019-02-27 2020-02-26 Method of treating a fibrotic disease or condition or of an interstitial lung disease using a src kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024146122A Division JP2024174909A (ja) 2019-02-27 2024-08-28 Ｓｒｃキナーゼ阻害剤を使用して線維性疾患若しくは線維性状態又は間質性肺疾患を処置する方法

Publications (3)

Publication Number Publication Date
JP2022521635A JP2022521635A (ja) 2022-04-11
JP2022521635A5 JP2022521635A5 (https=) 2023-03-06
JP7547356B2 true JP7547356B2 (ja) 2024-09-09

Family

ID=69784492

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021550035A Active JP7547356B2 (ja) 2019-02-27 2020-02-26 Ｓｒｃキナーゼ阻害剤を使用して線維性疾患若しくは線維性状態又は間質性肺疾患を処置する方法
JP2024146122A Pending JP2024174909A (ja) 2019-02-27 2024-08-28 Ｓｒｃキナーゼ阻害剤を使用して線維性疾患若しくは線維性状態又は間質性肺疾患を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024146122A Pending JP2024174909A (ja) 2019-02-27 2024-08-28 Ｓｒｃキナーゼ阻害剤を使用して線維性疾患若しくは線維性状態又は間質性肺疾患を処置する方法

Country Status (12)

Country Link
US (1) US20220117966A1 (https=)
EP (1) EP3930715B1 (https=)
JP (2) JP7547356B2 (https=)
CN (1) CN113811296B (https=)
DK (1) DK3930715T3 (https=)
ES (1) ES2994095T3 (https=)
FI (1) FI3930715T3 (https=)
HU (1) HUE067967T2 (https=)
MA (1) MA55076A (https=)
PT (1) PT3930715T (https=)
TW (1) TWI836022B (https=)
WO (1) WO2020174420A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112674031B (zh) * 2020-12-03 2021-11-30 同济大学 新型冠状病毒感染的啮齿动物模型的构建方法和用途
US20250161250A1 (en) * 2022-02-28 2025-05-22 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis
CN117618436A (zh) * 2022-08-25 2024-03-01 广州再极医药科技有限公司 一种稠环嘧啶类化合物的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
GB0427697D0 (en) 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
US9844528B2 (en) * 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
CN102675282B (zh) * 2011-03-15 2014-12-24 广东东阳光药业有限公司 取代的喹啉化合物及其使用方法和用途
US20130336889A1 (en) * 2012-06-14 2013-12-19 National Taiwan University Nanoparticle and method for detecting or treating a tumor using the same
CN105294682B (zh) * 2014-07-26 2017-07-07 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
EP4653015A3 (en) * 2015-01-26 2025-12-31 Yale University COMPOSITIONS AND METHODS OF USE OF TYROSINE KINASE INHIBITORS
EP3277282B1 (en) * 2015-04-01 2022-10-12 Istanbul Universitesi Rektorlugu Dasatinib for use in the treatment, regression or decelerating the progress of fibrotic lung diseases
GB201514760D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
JP6905662B2 (ja) * 2015-11-14 2021-07-21 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換キノリン化合物の結晶形およびその医薬組成物
EP3228630A1 (en) * 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
WO2018026441A1 (en) * 2016-08-01 2018-02-08 The Regents Of The University Of California Methods for preventing or treating fibrotic diseases
WO2018046876A1 (en) * 2016-09-06 2018-03-15 The University Of Birmingham Treatment of chronic inflammatory disease
CN106692150B (zh) * 2016-12-21 2019-08-20 中国人民解放军第三〇二医院 尼达尼布在制备预防和治疗肝纤维化与肝硬化的药物中的用途
EP3964214A1 (en) * 2020-09-02 2022-03-09 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Modulators of airway basal cells for the treatment or prevention of lung diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Alzheimer's Research & Therapy，2015年，7，35, pp.1-11
J Pharmacol Exp Ther.，2014年，351，pp.87-95
N Engl J Med.，2014年，370，pp.2071-2082
N Engl J Med.，2014年，370，pp.2083-2092

Also Published As

Publication number Publication date
CN113811296A (zh) 2021-12-17
PT3930715T (pt) 2024-08-02
ES2994095T3 (en) 2025-01-17
MA55076A (fr) 2022-04-20
DK3930715T3 (da) 2024-08-05
TWI836022B (zh) 2024-03-21
EP3930715B1 (en) 2024-05-08
HUE067967T2 (hu) 2024-12-28
JP2024174909A (ja) 2024-12-17
FI3930715T3 (fi) 2024-08-05
CN113811296B (zh) 2025-05-16
EP3930715A1 (en) 2022-01-05
JP2022521635A (ja) 2022-04-11
WO2020174420A1 (en) 2020-09-03
TW202045180A (zh) 2020-12-16
US20220117966A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
JP2024174909A (ja) Ｓｒｃキナーゼ阻害剤を使用して線維性疾患若しくは線維性状態又は間質性肺疾患を処置する方法
ES2476368T3 (es) Tratamiento de la artritis reumatoide con una combinación de laquinimod y metotrexato
AU2012321106B2 (en) Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent
AU2020203867A1 (en) Cenicriviroc for the treatment of fibrosis
JP7490635B2 (ja) Ｅｇｆｒ変異がんの処置
EP3038652B1 (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
US20200030302A1 (en) Treating Gastric Cancer Using Combination Therapies Comprising Liposomal Irinotecan, Oxaliplatin, 5-Fluoruracil (and Leucovorin)
CA2998509A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
CN108430475B (zh) 用于治疗慢性咳嗽的奥维匹坦
AU2019350581B2 (en) Methods of treatment of cancer comprising Cdc7 inhibitors
CN114650819A (zh) 用于治疗移植物排斥、闭塞性细支气管炎综合征和移植物抗宿主病的阿维来司他
AU2017358703A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
JP7751362B2 (ja) 乾癬性関節炎の治療方法
Kanesvaran et al. A single-arm phase 1b study of everolimus and sunitinib in patients with advanced renal cell carcinoma
JP2022533100A (ja) Ｎｏｔｃｈ活性化乳がんを治療するためのビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物
US20250312332A1 (en) Treatment of muscle fibrosis
CN114144229A (zh) 心血管功能障碍的性别依赖性治疗方法和材料
JP2022523028A (ja) 特発性肺線維症を処置するための方法
JP2025537141A (ja) 全身性硬化症を処置するための可溶性グアニル酸シクラーゼ活性化剤
CN115335507A (zh) 用于评估组合物在减少癌症治疗剂对皮肤的影响方面的功效的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240701

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240828

R150 Certificate of patent or registration of utility model

Ref document number: 7547356

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150